Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 82

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 82
---
 of Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of such warrants.
However, any holder may increase or decrease such percentage, provided that any increase will not be effective until the 61st day after
such election.

In the event of a Fundamental Transaction (as such
term is defined in the Inducement Warrants), then the successor entity will succeed to, and be substituted for the Company, and may exercise
every right and power that the Company may exercise and will assume all of its obligations under the Inducement Warrants with the same
effect as if such successor entity had been named in the warrant itself. If holders of Common Stock are given a choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the holder shall be given the same choice as to the consideration it
receives upon any exercise of the Inducement Warrants following such Fundamental Transaction. In addition, the successor entity, at the
request of holders of Inducement Warrants, will be obligated to purchase any unexercised portion of the Inducement Warrants in accordance
with the terms thereof. Notwithstanding the foregoing, in the event of a Fundamental Transaction, the holders of the Inducement Warrants
have the right to require the Company or a successor entity to redeem the Inducement Warrants for cash in the amount of the Black Scholes
Value (as defined in the Inducement Warrants) of the unexercised portion of the Inducement Warrants concurrently with or within 30 days
following the consummation of a Fundamental Transaction. However, in the event of a Fundamental Transaction which is not in the Company’s
control, including a Fundamental Transaction not approved by the Company’s board of directors, the holders of the Inducement Warrants
will only be entitled to receive from the Company or its successor entity the same type or form of consideration (and in the same proportion),
at the Black Scholes Value of the unexercised portion of the Inducement Warrant that is being offered and paid to the holders of Common
Stock in connection with the Fundamental Transaction, whether that consideration is in the form of cash, stock or any combination of cash
and stock, or whether the holders of Common Stock are given the choice to receive alternative forms of consideration in connection with
the Fundamental Transaction.

Except as otherwise provided in the Inducement Warrants
or by virtue of such holder